| (Values in U.S. Thousands) | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 |
| Sales | 61,450 | 59,670 | 62,500 | 56,220 | 59,140 |
| Sales Growth | +2.98% | -4.53% | +11.17% | -4.94% | +1.32% |
| Net Income | -7,890 | -10,630 | -9,690 | -9,660 | -8,970 |
| Net Income Growth | +25.78% | -9.70% | -0.31% | -7.69% | -4.06% |
Cardiovascular Syst (CSII)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cardiovascular Systems, Inc. is a medical device manufacturer that develops and commercializes innovative solutions to treat patients suffering from peripheral and coronary arterial diseases, including those with arterial calcium. The foundation of the company's business is catheter-based platforms, which are capable of treating a wide spectrum of vessel sizes and plaque types. The company sells its products through direct sales force in the United States. The company delivers a unique, patented Orbital Atherectomy System of products that remove calcified and fibrotic plaque in arterial vessels throughout the leg and heart in very short treatment time. These products address many of the limitations associated with standard surgical, catheter and pharmacological treatment alternatives. The company is investing in sales, marketing, medical education, clinical studies and product research and development for its next phase of growth in the peripheral market and continue the commercialization of its CAD System.
Fiscal Year End Date: 06/30